Maravai LifeSciences Holdings Inc. Class A Common Stock vs Waste Management, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Waste Management, Inc. trades at $216.76 (market cap $84.67B). The key difference: Waste Management, Inc. is far larger — about 87× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Waste Management, Inc. pays a 1.78% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Waste Management, Inc. for 131 Days on average.
| MRVI | WM | |
|---|---|---|
Market Cap | $972.90M | $84.67B |
Volume | 4,325,710 | 1,534,456 |
Sector | Health | Industrials |
52-Week High | $9.00 | $246.51 |
52-Week Low | $2.83 | $196.77 |
Typical Hold Time | 0 Days | 131 Days |
Enterprise Value | $1.08B | $107.47B |
Dividend Yield | — | 1.78% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
WM trades at $215.75, up 2.18% today, with a bullish technical signal despite mixed momentum indicators. The company reported strong revenue growth to $25.20 billion in 2025 and beat earnings estimates in two of the last three quarters. Analyst consensus is positive with 54% buy ratings, and the stock offers a dividend yield supported by robust cash flow from operations of $6.04 billion.
Outlook remains favorable due to pricing power and acquisition strategy, but elevated debt levels and a high P/E ratio of 29.96 pose risks. Near-term performance hinges on Q3 2026 earnings results expected on October 27, 2026, with investor focus on margin sustainability and debt management amid economic uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →